New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.

Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

So who else could be interested in the oestrogen degrader?

If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.

Weeks after criticising the group’s big pharma partner, John Houston is on his way out.

But camizestrant’s use could depend on uptake of monitoring – for now.

Any hopes of differentiation could come down to side effects.